Please use this identifier to cite or link to this item:
|Title:||Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections||Authors:||Chmiel, James F.
Aksamit, Timothy R.
Chotirmall, Sanjay Haresh
Dasenbrook, Elliott C.
Stuart Elborn, J.
LiPuma, John J.
Ranganathan, Sarath C.
Waters, Valerie J.
Ratjen, Felix A.
Methicillin-resistant Staphylococcus aureus
|Issue Date:||2014||Source:||Chmiel, J. F., Aksamit, T. R., Chotirmall, S. H., Dasenbrook, E. C., Stuart Elborn, J., LiPuma, J. J., et al. (2014). Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections. Annals of the American Thoracic Society, 11(7), 1120-1129.||Series/Report no.:||Annals of the American Thoracic Society||Abstract:||Despite significant advances in treatment strategies targeting the underlying defect in cystic fibrosis (CF), airway infection remains an important cause of lung disease. In this two-part series, we review recent evidence related to the complexity of CF airway infection, explore data suggesting the relevance of individual microbial species, and discuss current and future treatment options. In Part I, the evidence with respect to the spectrum of bacteria present in the CF airway, known as the lung microbiome is discussed. Subsequently, the current approach to treat methicillin-resistant Staphylococcus aureus, gram-negative bacteria, as well as multiple coinfections is reviewed. Newer molecular techniques have demonstrated that the airway microbiome consists of a large number of microbes, and the balance between microbes, rather than the mere presence of a single species, may be relevant for disease pathophysiology. A better understanding of this complex environment could help define optimal treatment regimens that target pathogens without affecting others. Although relevance of these organisms is unclear, the pathologic consequences of methicillin-resistant S. aureus infection in patients with CF have been recently determined. New strategies for eradication and treatment of both acute and chronic infections are discussed. Pseudomonas aeruginosa plays a prominent role in CF lung disease, but many other nonfermenting gram-negative bacteria are also found in the CF airway. Many new inhaled antibiotics specifically targeting P. aeruginosa have become available with the hope that they will improve the quality of life for patients. Part I concludes with a discussion of how best to treat patients with multiple coinfections.||Description:||35 p.||URI:||https://hdl.handle.net/10356/80750
|ISSN:||2329-6933||DOI:||10.1513/AnnalsATS.201402-050AS||Schools:||Lee Kong Chian School of Medicine (LKCMedicine)||Rights:||© 2014 American Thoracic Society. This is the author created version of a work that has been peer reviewed and accepted for publication by Annals of the American Thoracic Society, American Thoracic Society. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1513/AnnalsATS.201402-050AS].||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||LKCMedicine Journal Articles|
Files in This Item:
|Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections.pdf||349.26 kB||Adobe PDF|
Updated on Sep 11, 2023
Page view(s) 20588
Updated on Sep 29, 2023
Updated on Sep 29, 2023
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.